Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...

Hengrui's GLP-1/GIP drug shows 22.8% weight loss at 36 weeks in Phase 2, beating Eli Lilly's retatrutide. Kailera ...

AbbVie partners with Simcere Zaiming in up to $1.1B deal to develop SIM0500 for multiple myeloma; drug currently in Phase 1 ...

Eli Lilly, the most talked-about pharmaceutical company in recent years, is buying cancer startup Scorpion Therapeutics about ...

Indian CDMO Aragen has secured a $100 million investment from Singapore-headquartered private equity firm Quadria Capital.

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...

Gilead licenses Leo Pharma's oral STAT6 portfolio for inflammatory diseases in $250M upfront deal, potentially worth $1.7B, ...

Regor Therapeutics' oral obesity drug RGT-075 shows 5% weight loss at 12 weeks in Phase 2a, trailing incretin pills from ...

John­son & John­son is ac­quir­ing In­tra-Cel­lu­lar Ther­a­pies for $14.6 bil­lion in the biggest biotech M&A trans­ac­tion ...

Radiopharmaceutical maker Lantheus Holdings plans to acquire Life Molecular Imaging for $350 million in a bid to build up its ...

Immunovant secures $450M private placement for IMVT-1402 development, while Biomea shifts focus to diabetes, and multiple companies announce deals and organizational changes.

L1 pioneer Lieping Chen has closed a new financing round. Normunity raised $75 million in a Series B, the company announced Monday, which it hopes to use to advance its lead program NRM-823 into the ...